AIM:IXI · Health Care · Specialist neuroimaging/biomarker analytics contract research organisation (iCRO) serving the global biopharmaceutical industry, AIM-listed (ticker: IXI)

Ixico plc

IXICO plc is an AIM-quoted, UK-domiciled imaging Contract Research Organisation (iCRO) and AI-driven biomarker analytics company serving the global biopharmaceutical industry. Its proprietary IXI platform analyses MRI/PET/SPECT neuroimaging data to support clinical trials and drug development in neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's. The Group also supports diagnostic validation (e.g. blood-based biomarkers) and post-market surveillance beyond core clinical-trial imaging services.

Export the Ixico plc factsheetfree account Open the FY2025 report

Share price and financials

7.8p at close on 16 Oct 2026 · 11 reported years, FY2015–FY2025

Years in viewFY2015 – FY2026

16 Oct 20267.8p−75.0% since 4 Jan 2016 58k traded

7.8p

Line	FY2015locked	FY2016locked	FY2017locked	FY2018locked	FY2019locked	FY2020locked	FY2021locked	FY2022locked
Revenue	6.8	4.1	8.1	8.6	6.7	7.1	7.5	3.7
Gross profit	1.9	1.7	2.1	3.8	2.3	2.1	4.2	4.1
Operating profit	(2.6)	(1.9)	(2.8)	(1.7)	(1.8)	(2.8)	(1.6)	(1.4)
Net finance cost	(0.09)	(0.05)	(0.06)	(0.10)	(0.09)	(0.12)	(0.06)	(0.11)
Profit before tax	(2.3)	(1.2)	(1.7)	(2.4)	(2.6)	(2.2)	(1.5)	(2.3)
Tax charge	(0.24)	(0.51)	(0.48)	(0.44)	(0.46)	(0.32)	(0.23)	(0.51)
Profit for the year	(0.98)	(2.3)	(1.7)	(1.7)	(1.1)	(0.90)	(1.1)	(2.3)
EBITDA	(1.4)	(2.1)	(1.5)	(0.89)	(2.0)	(1.7)	(0.91)	(1.0)
Basic EPS	(1.73p)	(2.46p)	(3.07p)	(2.53p)	(3.15p)	(3.85p)	(3.34p)	(2.02p)
Diluted EPS	(1.75p)	(2.35p)	(3.75p)	(2.55p)	(3.06p)	(2.07p)	(1.95p)	(2.41p)

GBP millions, negatives in brackets. Per-share lines in pence. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.

2 figures

3 years, at a glance

GBP · %

Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.

FY2025Revenue£6.5mOperating margin−39.1%